{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:30:34Z","timestamp":1776889834062,"version":"3.51.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health, Labor and Welfare Sciences Research Grant for Research on Rare and Intractable Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cerebrotendinous xanthomatosis (CTX) is an autosomal-recessive lipid storage disorder caused by mutations in the <jats:italic>CYP27A1<\/jats:italic> gene encoding the key enzyme in the bile acid synthesis, sterol 27-hydroxylase. Here, we report two Japanese CTX siblings with a novel compound heterozygous <jats:italic>CYP27A1<\/jats:italic> mutation, showing different clinical phenotypes and responses to chenodeoxycholic acid (CDCA) therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The proband, a 32-year-old man, who had chronic diarrhea, bilateral cataracts, and xanthomas, demonstrated progressive neurological manifestations including ataxia, and spastic paraplegia during a 5-year follow-up period despite normalization of serum cholestanol after initiation of CDCA treatment. He also exhibited cognitive decline although improvement had been observed at the beginning of treatment. Follow-up brain magnetic resonance imaging (MRI) revealed pronounced progressive atrophy in the cerebellum, in addition to expanding hyperintense lesions in the dentate nuclei, posterior limb of the internal capsule, cerebral peduncles, and inferior olives on T2-weighted images. In contrast, the two-year-younger sister of the proband presented with chronic diarrhea, cataracts, xanthomas, and intellectual disability but no other neurological symptoms at the time of diagnosis. CDCA treatment lead to improvement of cognitive function and there were no characteristic CTX-related MRI features during the follow-up period. The siblings shared a paternally inherited c.1420C\u2009&gt;\u2009T mutation (p.Arg474Trp) and a maternally inherited novel c.1176_1177delGA mutation, predicting p.(Glu392Asp*20).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our cases suggest that early diagnosis and subsequent initiation of CDCA treatment are crucial before the appearance of characteristic MRI findings and severe neurological manifestations related to CTX. Further studies are required to elucidate mechanisms responsible for the clinical diversity of CTX and prognostic factors for long-term outcomes following initiation of CDCA treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02711-4","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:03:58Z","timestamp":1653455038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-059X","authenticated-orcid":false,"given":"Shingo","family":"Koyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Igari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chifumi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyo","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"2711_CR1","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.1016\/S0021-9258(20)89518-0","volume":"266","author":"JJ Cali","year":"1991","unstructured":"Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266:7779\u201383.","journal-title":"J Biol Chem"},{"key":"2711_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/brain\/123.5.908","volume":"123","author":"A Verrips","year":"2000","unstructured":"Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabre\u00ebls FJ, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain. 2000;123:908\u201319.","journal-title":"Brain"},{"key":"2711_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1468-1331.2011.03439.x","volume":"18","author":"B Pilo-de-la-Fuente","year":"2011","unstructured":"Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18:1203\u201311.","journal-title":"Eur J Neurol"},{"key":"2711_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10545-013-9674-3","volume":"37","author":"A Mignarri","year":"2014","unstructured":"Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014;37:421\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"2711_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-014-0179-4","volume":"9","author":"S Nie","year":"2014","unstructured":"Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9:179.","journal-title":"Orphanet J Rare Dis"},{"key":"2711_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10545-017-0093-8","volume":"40","author":"G Salen","year":"2017","unstructured":"Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis. 2017;40:771\u201381.","journal-title":"J Inherit Metab Dis"},{"key":"2711_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10545-018-0152-9","volume":"41","author":"JC Wong","year":"2018","unstructured":"Wong JC, Walsh K, Hayden D, Eichler FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41:647\u201356.","journal-title":"J Inherit Metab Dis"},{"key":"2711_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacl.2018.06.008","volume":"12","author":"PB Duell","year":"2018","unstructured":"Duell PB, Salen G, Eichler FS, DeBarber AE, Connor SL, Casaday L, et al. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol. 2018;12:1169\u201378.","journal-title":"J Clin Lipidol"},{"key":"2711_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s10038-017-0389-4","volume":"63","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Koyama S, Yoshinaga T, Koinuma M, Inaba Y. Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet. 2018;63:271\u201380.","journal-title":"J Hum Genet"},{"key":"2711_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJM198412273112601","volume":"311","author":"VM Berginer","year":"1984","unstructured":"Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311:1649\u201352.","journal-title":"N Engl J Med"},{"key":"2711_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s004310050818","volume":"157","author":"AF van Heijst","year":"1998","unstructured":"van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr. 1998;157:313\u20136.","journal-title":"Eur J Pediatr"},{"key":"2711_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/WNF.0b013e318288076a","volume":"36","author":"G Yahalom","year":"2013","unstructured":"Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013;36:78\u201383.","journal-title":"Clin Neuropharmacol"},{"key":"2711_CR13","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000006731","volume":"92","author":"BML Stelten","year":"2019","unstructured":"Stelten BML, Huidekoper HH, van de Warrenburg BPC, Brilstra EH, Hollak CEM, Haak HR, et al. Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology. 2019;92:e83\u201395.","journal-title":"Neurology"},{"key":"2711_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10072-006-0618-7","volume":"27","author":"GN Gallus","year":"2006","unstructured":"Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci. 2006;27:143\u20139.","journal-title":"Neurol Sci"},{"key":"2711_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405\u201314.","journal-title":"Genet Med"},{"key":"2711_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1212\/WNL.46.2.571","volume":"46","author":"Y Nagai","year":"1996","unstructured":"Nagai Y, Hirano M, Mori T, Takakura Y, Tamai S, Ueno S. Japanese triplets with cerebrotendinous xanthomatosis are homozygous for a mutant gene coding for the sterol 27-hydroxylase (Arg441Trp). Neurology. 1996;46:571\u20134.","journal-title":"Neurology"},{"key":"2711_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejmg.2011.08.003","volume":"55","author":"S Suh","year":"2012","unstructured":"Suh S, Kim HK, Park HD, Ki CS, Kim MY, Jin SM, et al. Three siblings with cerebrotendinous xanthomatosis: a novel mutation in the CYP27A1 gene. Eur J Med Genet. 2012;55:71\u20134.","journal-title":"Eur J Med Genet"},{"key":"2711_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10072-016-2776-6","volume":"38","author":"D Z\u00e1dori","year":"2017","unstructured":"Z\u00e1dori D, Szpisjak L, Madar L, Varga VE, Cs\u00e1nyi B, Bencsik K, et al. Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series. Neurol Sci. 2017;38:481\u20133.","journal-title":"Neurol Sci"},{"key":"2711_CR19","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00415-019-09377-y","volume":"266","author":"D Mandia","year":"2019","unstructured":"Mandia D, Besson G, Lamari F, Castelnovo G, Curot J, Duval F, et al. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol. 2019;266:2043\u201350.","journal-title":"J Neurol"},{"key":"2711_CR20","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s00415-017-8440-0","volume":"264","author":"A Mignarri","year":"2017","unstructured":"Mignarri A, Dotti MT, Federico A, De Stefano N, Battaglini M, Grazzini I, et al. The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol. 2017;264:862\u201374.","journal-title":"J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02711-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:05:40Z","timestamp":1653455140000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02711-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02711-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"24 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the Yamagata University Faculty of Medicine. Written informed consent was obtained from the patients and their family members.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients and their family members for publication of this report and the accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}